RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
Stem cell therapy for cerebral palsy in South Korea typically costs between AUD $26,608 and AUD $50,339. Final prices depend on the cell source, delivery method, and length of hospital stay. In Australia, limited access and high private costs make this treatment expensive, with average prices around AUD $37,395. Australians can save approximately 29% by travelling to medical hubs like Seoul or Cheonan. Packages generally include consultations, cell processing, and initial rehabilitation.
Bookimed Expert Insight: Choosing arterial delivery can offer superior value for neurological conditions. RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) in Cheonan specialises in this technique. It delivers cells directly to the brain, which may improve efficacy compared to systemic IV injections. The clinic is accredited by KOIHA, south Korea’s healthcare quality body. Specialist neurologists like Yeon Jung Kim at major Seoul centres provide the expert evaluations needed for these complex treatments.
| Republic of Korea | Thailand | Turkey | |
| Stem cell therapy for cerebral palsy | from AUD $26,608 | from AUD $21,574 | from AUD $21,574 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem cell therapy for cerebral palsy upon arrival and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem cell therapy for cerebral palsy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem cell therapy for cerebral palsy journey.
Stem cell therapy for cerebral palsy is available in Republic of Korea. However, it remains an investigational treatment rather than a standard, routine procedure. Facilities in Seoul and Cheonan offer delivery methods like arterial infusion. Patients often access these therapies through clinical trials or specialised regenerative medicine centres.
Bookimed Expert Insight: While many countries use intravenous injections, Korean clinics like RE:YOUTH specialise in direct arterial infusion. This method delivers stem cells closer to the brain tissue. They also limit intake to only 2 patients daily to maintain high care standards.
Patient Consensus: Recent research in Korea focuses on growing brain cells from stem cells to restore function. Many families recommend consulting an Australian paediatric neurologist to review the latest trial evidence. This should happen before booking travel.
Stem cell therapy in the Republic of Korea aims to improve motor function and cognitive abilities in patients with cerebral palsy. Clinical research indicates a functional score increase of roughly 30.7% within 6 months. Specialist centres focus on umbilical cord blood infusions to enhance independence and physical coordination.
Bookimed Expert Insight: Most global clinics use standard IV drips. South Korea’s RE:YOUTH clinic, however, specialises in direct arterial infusion. This method delivers cells more effectively to targeted areas. Dr Sang Hoon Shin and Dr Yeon Jung Kim lead the oversight. Their work takes place at KOIHA-accredited facilities.
Patient Consensus: Families highlight verifying clinical trial data. They also stress consulting Australian neurologists before travelling. Success often depends on combining these infusions with physical therapy. The therapy must be intensive, ongoing, and provided in the Republic of Korea.
Republic of Korea is a world leader in regenerative medicine. It offers arterial stem cell therapy for neurological conditions. Patients access facilities like RE:YOUTH, which hold KOIHA accreditation. Treatment involves specialised protocols. These are delivered by expert neurologists such as Dr. Yeon Jung Kim and Dr. Sang Hoon Shin.
Bookimed Expert Insight: Many countries offer standard intravenous stem cell therapy. However, Korean clinics specialise in arterial infusion. This method delivers cells directly toward the brain through the carotid artery. Data shows some clinics serve 1,000+ patients annually using this intensive approach.
South Korean protocols for cerebral palsy primarily use allogeneic umbilical cord blood stem cells. These donor cells are often delivered via arterial injection to reach the brain directly. Clinics such as RE:YOUTH specialise in this direct infusion method. The method bypasses lung filtering and improves efficiency.
Bookimed Expert Insight: While many countries use intravenous drips, South Korea leads in arterial infusion for neurological conditions. Only one facility currently offers this specific direct-to-brain delivery: RE:YOUTH (YONSEI BH Arterial Stemcell Clinic). This method aims for higher cell concentration in the brain compared to standard IV methods.
Patient Consensus: Families advise asking clinics for evidence supporting specific cell types. These include autologous or allogeneic mesenchymal cells. Practical experience suggests confirming Ministry of Food and Drug Safety approval. This approval is for any experimental cerebral palsy protocol.
Patients typically observe initial improvements from stem cell therapy for cerebral palsy within 3 to 6 months. These gradual changes usually involve enhanced motor function, reduced muscle tone, or better cognitive awareness. Full therapeutic effects often take 1 to 2 years to develop alongside intensive physical rehabilitation.
Bookimed Expert Insight: Most clinics focus on intravenous delivery. However, the arterial approach at RE:YOUTH in Cheonan is unique in Korea. Evidence suggests this targeted method helps cells reach damaged brain tissue more efficiently. This difference is critical for patients who have not responded to standard systemic treatments.
Patient Consensus: Real experiences show that improvements are subtle. They also require months of dedicated rehabilitation in Republic of Korea. Families find that combining therapy with evidence-based management provides the most consistent physical progress.
Specialists in the Republic of Korea administer stem cells through intravenous (IV) infusion. They may also use intrathecal injection into the spinal fluid or direct arterial infusion. Leading facilities like CHA Bundang Medical Centre and RE:YOUTH Clinic follow strict safety standards. These are set by the Korean Institute for Healthcare Accreditation (KOIHA).
Bookimed Expert Insight: While most global centres rely on standard IV drips, Korean clinics like RE:YOUTH specialise in arterial infusion. This method is rare and aims for higher cell concentration in the brain. The clinic even limits intake to two patients daily to maintain VIP-level care quality.
Patient Consensus: Families recommend confirming whether the administration route is intrathecal or intra-arterial before booking. They suggest checking that the clinic holds KOIHA accreditation for experimental cerebral palsy protocols in Korea.
Republic of Korea has no strictly defined government age limit for stem cell therapy for cerebral palsy. Instead, clinics focus on neurological plasticity and individual eligibility. Practitioners like Dr Sang Hoon Shin treat diverse cases. However, most facilities prioritise children aged 6–10 for better results.
Bookimed Expert Insight: While age limits are flexible, the type of delivery matters greatly in Korea. RE:YOUTH is currently the only facility offering arterial stem cell therapy specifically. This targeted approach is often restricted to very few patients per day. Doing so ensures VIP-level care standards.
Patient Consensus: Parents found that Korean clinics often market to those under age 10 for best outcomes. They suggest checking specific hospital cutoffs early. Many facilities decline teenagers over 14 years old.